OraSure Recalls ORA-Collect DNA Device Over Contamination
Ticker: OSUR · Form: 8-K · Filed: Apr 12, 2024 · CIK: 1116463
| Field | Detail |
|---|---|
| Company | Orasure Technologies Inc (OSUR) |
| Form Type | 8-K |
| Filed Date | Apr 12, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.000001 |
| Sentiment | bearish |
Sentiment: bearish
Topics: product-recall, contamination, regulatory-disclosure
Related Tickers: OSUR
TL;DR
OraSure recalling DNA kits due to contamination, Q2 earnings gonna hurt.
AI Summary
On April 10, 2024, OraSure Technologies, Inc. announced a voluntary recall of its ORA-Collect DNA Sample Collection Device due to potential contamination issues. The company is working with regulatory bodies and has initiated a process to notify customers and provide instructions for product return or disposal. This recall is expected to impact the company's financial results for the second quarter of 2024.
Why It Matters
This recall could lead to lost revenue and increased costs for OraSure Technologies, potentially impacting customer trust and future sales of the affected product line.
Risk Assessment
Risk Level: medium — The recall of a key product due to contamination poses a direct risk to revenue and customer confidence.
Key Players & Entities
- OraSure Technologies, Inc. (company) — Registrant
- ORA-Collect DNA Sample Collection Device (product) — Recalled item
- April 10, 2024 (date) — Date of report
- second quarter of 2024 (date) — Impacted financial period
FAQ
What specific contamination issue led to the recall of the ORA-Collect DNA Sample Collection Device?
The filing does not specify the exact nature of the contamination, only that it is a 'potential contamination issue'.
What is OraSure Technologies' plan to address the recall?
OraSure is working with regulatory bodies, notifying customers, and providing instructions for product return or disposal.
Which specific product is being recalled?
The ORA-Collect DNA Sample Collection Device is being recalled.
When was the recall announced?
The recall was announced on April 10, 2024.
What is the expected financial impact of this recall?
The recall is expected to impact OraSure Technologies' financial results for the second quarter of 2024.
Filing Stats: 888 words · 4 min read · ~3 pages · Grade level 13.8 · Accepted 2024-04-12 16:45:30
Key Financial Figures
- $0.000001 — nge on which registered Common Stock, $0.000001 par value per share OSUR The NASDAQ
Filing Documents
- d825009d8k.htm (8-K) — 28KB
- 0001193125-24-094797.txt ( ) — 145KB
- osur-20240410.xsd (EX-101.SCH) — 3KB
- osur-20240410_lab.xml (EX-101.LAB) — 17KB
- osur-20240410_pre.xml (EX-101.PRE) — 11KB
- d825009d8k_htm.xml (XML) — 3KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are based on management's current expectations and assumptions, are not based on historical facts and are subject to risks and uncertainties, and other important factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements and can be identified by the fact that they do not relate strictly to historical or current facts and may contain the words "believe," "anticipate," "estimate," "expect," "will," or other similar words and phrases or future or conditional verbs such as "could", "may," "will," or "would." Readers are cautioned not to place undue reliance on our forward-looking statements, as they speak only as of the date made. We disclaim any obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Item9.01
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ORASURE TECHNOLOGIES, INC. Date: April 12, 2024 By: /s/ Carrie Eglinton Manner Carrie Eglinton Manner President and Chief Executive Officer